Retrospective review of Her2 positive metastatic breast cancer patients who received Pertuzumab and Herceptin as a first line therapy at KFSH&RC (single institute experience) from 2013 to 2016. (March 2019) - Suleman, K.; Mushtaq, A.; Haque, E.; Badran, A.; Ajarim, D.; Tweigeri, T.; Elashwah, A.; Shahin, A.; Khan, K.; Alsayed, A.